Like many industries, Pharma’s business model fundamentally depends on productive innovation to create value by delivering greater customer benefits. Further, sustainable growth and value creation depend on steady R&D productivity with a positive return on investment (ROI), in order to drive future revenues that can be re-invested back into R&D. In recent years, however, it has become clear that Pharma has a serious problem with declining R&D productivity.

What is clear is that Pharma (and Biopharma) will not be around forever, and Darwin’s theory of evolution applies to companies and industries just as much as it applies to the species of life:

It is not the strongest of the species that survives, nor the most intelligent, but the one most adaptable to change.

Click here to access Kelvin Stott’s recently published LinkedIn article on the subject.